The North America infectious disease therapeutics market was valued at US$ 46.37 billion in 2022 and is expected to reach US$ 65.95 billion by 2030; it is estimated to register a CAGR of 4.5% from 2022 to 2030.
Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate.
Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection.
In September 2021, the Biden-Harris Administration invested US$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.
Rising Prevalence of Infectious Disease Fuels North America Infectious Disease Therapeutics Market
Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women.Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate.
Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
North America Infectious Disease Therapeutics Market Overview
The infectious disease therapeutics market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US.Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection.
In September 2021, the Biden-Harris Administration invested US$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.
North America Infectious Disease Therapeutics Market Segmentation
The North America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.- Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
- In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
- Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
- In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
- By country, the North America infectious disease therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease therapeutics market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Infectious Disease Therapeutics Market - Key Market Dynamics
5. Infectious Disease Therapeutics Market - North America Market Analysis
6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class
7. North America Infectious Disease Therapeutics Market Analysis - by Indication
8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration
9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
10. North America Infectious Disease Therapeutics Market - Country Analysis
11. Infectious Disease Therapeutics Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- AbbVie Inc
- Astellas Pharma Inc
- Bayer AG
- BioCryst Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- GSK Plc
- Merck & Co Inc
- Pfizer Inc
- Shionogi & Co Ltd
